Clearline Capital’s GSK GSK Stock Holding History

Clearline Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-116,324	Closed	-$5.59M	–	60
2015 Q3	$5.59M	Hold	116,324	–	–	0.94%	27
2015 Q2	$6.06M	Buy	+116,324	New	+$6.55M	0.84%	30

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Clearline Capital's GSK Position: Q4 2015 in Review

Clearline Capital sold out of GSK (GSK) in Q4 2015, closing a stake of 116,324 shares — an estimated $5.59M sold.

Clearline Capital first reported a position in GSK in Q2 2015 and held it in 2 quarters. The position peaked at $6.06M in Q2 2015. 718 funds tracked by Wall St. Rank hold GSK as of Q4 2015.

Clearline Capital reported no remaining GSK position as of Q4 2015 after selling out during the quarter.
Clearline Capital sold 116,324 GSK shares in Q4 2015, an estimated $5.59M.
Clearline Capital first reported a position in GSK in Q2 2015 and held it in 2 quarters.
Clearline Capital's GSK position peaked at $6.06M in Q2 2015.
718 funds tracked by Wall St. Rank held GSK as of Q4 2015.

Based on Clearline Capital's 13F filing for Q4 2015, filed 16 Feb 2016.